https://www.selleckchem.com/pr....oducts/durvalumab.ht
The aim of this study is to quantify the burden caused by viral hepatitis in China from 1990 to 2016. Data from the GBD 2016 study were extracted to calculate incidence, prevalence and disability-adjusted life years (DALYs). Trends in DALYs were assessed in 33 provinces/regions. From 1990 to 2016, the total incidence of hepatitis decreased by 88.5%. However, the prevalence of hepatitis (counts in thousands), increased by 37.6% from 153,856 (95% UI 136,047-172,319) in 1990 to 211,721 (95% UI 179,776-240,981) in 2016, with age-standard
Beğen
Yorum Yap
Paylaş
